Head-to-head · WeighScore
Primary Clinic (Direct GLP) vs Sumbare Wellness
The verdict
Primary Clinic (Direct GLP) takes it — 65.5/100 to 61.9/100.
Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Primary Clinic (Direct GLP) | Sumbare Wellness |
|---|---|---|
| WeighScore | 65.5/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #219 | #281 |
| Semaglutide | $85/mo (0.25-0.75 mg band, membership required, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $133/mo (1.25-2.5 mg band, membership required, compounded) | $199/mo (all doses, compounded) |
| Coverage | 10 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #219 · C
Strengths
- Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- Routine labs and thousands of medications included in membership — no surprise bills
- Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
Where it loses points
- The medication price is on top of an $89/mo direct-primary-care membership, which the FAQ states does not include the drug — all-in is about $174/mo for semaglutide and $222/mo for tirzepatide
- Prices are published as dose BANDS rather than per dose, and the cheapest tirzepatide band starts at 1.25 mg, below the 2.5 mg labelled starting dose
- The pricing is rendered entirely in JavaScript, so nothing on the page is readable without running the site's bundle
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #281 · C
Strengths
- One flat $199/month price covering medication, provider review and shipping, with no consultation fee and no dose-change surcharge
- Charges nothing if a provider does not approve you
- Offers a deliberate low-dose microdosing protocol aimed at body composition, which most competitors do not break out
- Publishes a named legal entity, a US mailing address and a working phone number
- Pre-screening quiz is short and asks your goal before any medical question
Where it loses points
- Cancellation terms contradict three ways: the homepage says cancel anytime, the Terms say 48 hours notice, the FAQ says 30 days
- Availability is unclear: the homepage counter reads 3 states while the treatment pages say telehealth nationwide, and no state list is published
- Its chart cites placebo-controlled trials of compounded semaglutide and tirzepatide, which do not exist; those trials studied the branded drugs
- No compounding pharmacy is named, and neither 503A nor 503B appears anywhere on the site
- Any returned prescription is charged a $35 disposal fee, and prescription orders cannot be cancelled at all after 24 hours
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.